| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SNAI1 |
| Uniprot No | O95863 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-264aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMPRSFLV RKPSDPNRKP NYSELQDSNP EFTFQQPYDQ AHLLAAIPPP EILNPTASLP MLIWDSVLAP QAQPIAWASL RLQESPRVAE LTSLSDEDSG KGSQPPSPPS PAPSSFSSTS VSSLEAEAYA AFPGLGQVPK QLAQLSEAKD LQARKAFNCK YCNKEYLSLG ALKMHIRSHT LPCVCGTCGK AFSRPWLLQG HVRTHTGEKP FSCPHCSRAF ADRSNLRAHL QTHSDVKKYQ CQACARTFSR MSLLHKHQES GCSGCPR |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SNAI1重组蛋白的3篇参考文献示例(文献名称和作者为虚构，内容基于典型研究方向概括)：
1. **《重组SNAI1蛋白诱导上皮间质转化的分子机制研究》**
*作者：Zhang L. 等人*
摘要：本研究通过大肠杆菌表达系统纯化重组人源SNAI1蛋白，探究其在体外对乳腺癌细胞上皮间质转化(EMT)的调控作用。实验表明，重组SNAI1蛋白可通过抑制E-cadherin表达并激活Wnt/β-catenin通路促进肿瘤细胞迁移。
2. **《SNAI1重组蛋白的制备及其在转移性前列腺癌模型中的应用》**
*作者：Wang Y. 等*
摘要：利用昆虫杆状病毒系统高效表达SNAI1重组蛋白，验证其与DNA结合活性。体内实验显示，该蛋白通过增强肿瘤微环境中基质细胞的促转移特性，加速前列腺癌骨转移进程。
3. **《基于重组SNAI1蛋白的靶向药物筛选平台构建》**
*作者：Kimura T. 等*
摘要：开发了一种基于表面等离子体共振(SPR)技术的SNAI1重组蛋白活性检测方法，筛选出小分子抑制剂Compound X，可特异性阻断SNAI1与组蛋白去乙酰化酶(HDAC)的相互作用，抑制EMT相关基因表达。
---
**注**：以上为模拟文献示例，实际研究中建议通过PubMed或Web of Science以“SNAI1 recombinant protein”等关键词检索最新论文。真实文献可能涉及重组蛋白的晶体结构解析、功能验证或作为工具分子应用于疾病模型研究。
SNAI1 (Snail Family Transcriptional Repressor 1) is a zinc-finger transcription factor that plays a pivotal role in epithelial-mesenchymal transition (EMT), a biological process critical during embryonic development, tissue repair, and cancer metastasis. It binds to E-box sequences in target gene promoters, repressing epithelial markers like E-cadherin (CDH1) while promoting mesenchymal traits. Dysregulation of SNAI1 is strongly associated with tumor progression, as it enhances cancer cell invasiveness, drug resistance, and stemness.
Recombinant SNAI1 protein is engineered for in vitro studies to dissect its molecular mechanisms. Produced using expression systems like *E. coli* or mammalian cells, the protein is purified to retain functional activity, often validated via DNA-binding assays or cellular EMT models. Researchers utilize it to investigate SNAI1 interactions with co-regulators (e.g., HDACs or β-catenin), its post-translational modifications (e.g., phosphorylation by GSK-3β), and its role in signaling pathways (e.g., TGF-β, Wnt).
In cancer research, recombinant SNAI1 helps model metastasis and screen therapeutic agents targeting EMT. It also aids in antibody development for diagnostic applications. Despite challenges in maintaining solubility and stability due to its intrinsically disordered regions, advancements in protein engineering have improved its utility. Studies using recombinant SNAI1 continue to clarify its context-dependent roles, offering insights into potential strategies to inhibit pathological EMT in fibrosis and metastatic diseases.
×
